Evaluating promotional material from industry: An evidence-based approach

Pharmaceutical Journal

Volumn 274, Issue 7339, 2005, Pages 271-274

  Pegler, Scott ^a   Underhill, Jonathan ^b  

^a ABERTAWE BRO MORGANNWG UNIVERSITY HEALTH BOARD   (United Kingdom)

^b National Prescribing Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CELECOXIB; CLASS; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO; ROFECOXIB; ROSUVASTATIN; SIMVASTATIN; TESTOSTERONE; VIGOR;

ARTICLE; AWARENESS; BLEEDING; CLINICAL TRIAL; COMMERCIAL PHENOMENA; DRUG CHOICE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EVALUATION; EVIDENCE BASED MEDICINE; FEMALE SEXUAL DYSFUNCTION; GASTROINTESTINAL TOXICITY; HEALTH EDUCATION; HEALTH PRACTITIONER; HEALTH PROMOTION; HUMAN; INFORMATION PROCESSING; MASS MEDIUM; MEDICAL DECISION MAKING; MEDICAL LITERATURE; POSTAL MAIL; PRESCRIPTION; RISK ASSESSMENT; RISK REDUCTION; STATISTICAL SIGNIFICANCE; STOMACH ULCER; UNSTABLE ANGINA PECTORIS; VALIDATION PROCESS;

EID: 15044358347     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. www.nofreelunch-uk.org/about.shtml (accessed 7 February 2005).
2. Devlin J, Hemsley P. Management views on industry issues, pressures and consultants. Scrip Magazine 1997;June 16:183.
3. www.nofreelunch.org/factsfallacies.htm (accessed 7 February 2005).
4. Moynihan R. The marketing of a disease: female sexual dysfunction. BMJ 2005;330:192-4.
5. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ 2002;324:886-91.
6. Villanueva P, Peiro S, Librero J, Pereiro I. Accuracy of pharmaceutical advertisements in medical journals. Lancet 2003;351.27-32.
7. Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. JAMA 1995;273:1296-8.
8. Shaughnessy AF, Slawson DC, Bennett JH. Becoming an information master: a guidebook to the medical information jungle. Journal of Family Practice 1994;39:489-99.
9. Mansfield PR. Healthy Skepticism's new AdWatch: understanding drug promotion. The Medical Journal of Australia 2003;179:664-5.
10. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al. VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New England Journal of Medicine 2000;343:1520-8.
11. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
12. COX-2 inhibitors update: do journal publications tell the full story? Therapeutics letter No 43 Nov/Dec/Jan 2001-2. Available at www.ti.ubc.ca/pages/letter43.htm (accessed 11 January 2005).
13. Rochon PA, Berger PB, Gordon M. The evolution of clinical trials: inclusion and representation. Canadian Medical Association Journal 1998;159:1373-4.
14. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? American Journal of Psychiatry 2002;159:469-73.
15. Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, Begaud B et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. British Journal of Rheumatology 1998;37:937-45.
16. Dequeker J, Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E et al. Improvement in gastrointestinal tolerability of the selective cyclo-oxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis. British Journal of Rheumatology 1998;37:946-51.
17. Committee on Safety of Medicines. Non-steroidal anti-inflammatory drugs (NSAIDs) and gastrointestinal (GI) safety. Current Problems in Pharmacovigilance 2002;28:5.
18. The Clopidogrel in Unstable Angina to prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-elevation. New England Journal of Medicine 2001;345:494-502.
19. National Electronic Library for Health. Heart drug that could save 10,000 lives a year. Available a www.nelh.nhs.uk/hth/clopidogrel.asp (accessed 11 January 2005).
20. Del Mar CB, Glasziou PP, Spinks AB. Antibiotics for sore throat. The Cochrane Database of Systematic Reviews 2004, Issue 2.
21. Tramèr MR, Reynolds DJM, Moore RA, McQuay HJ. Impact of covert duplicate publication on meta-analysis: a case study. BMJ 1997;315:635-40.
22. Preskorn SH, Antidepressant drug selection: criteria and options. Journal of Clinical Psychiatry 1994;55(suppl A):6-22, 23-4, 98-100.
23. Barber N. What constitutes good prescribing? BMJ 1995;310:923-5.